口溶锭(ODT) 市场：依药物类别、依疾病适应症、依年龄层、依配销通路、按地区

预计2023年全球口溶锭市场规模将达92.9亿美元。在预测期内，全球口腔崩坏锭剂市场预计将呈现约10.7%的年复合成长率(CAGR)。到2030年，市场规模预计将达到189.2亿美元。

图 1.口溶锭的全球市场占有率（%），按地区划分，2023 年

口溶锭(ODT) 是固态单位剂型，无需咀嚼或喝水即可在口腔中快速崩坏或溶解。这种剂型的需求正在增加，特别是在吞嚥传统锭剂困难或不舒服的儿童和老年患者群体中。 ODT 由多种赋形剂配製而成，包括粘合剂和崩坏。最常见的粘合剂是甲基丙烯酸共聚物，其具有较高的内部强度，可以支持高剂量药物的配方。它们还具有防水性，并且比标准锭剂对湿气更敏感。最常见的崩坏是甘露醇和阿斯巴甜。口溶锭( ODT) 是专门设计用于在口腔中快速崩坏（通常在几秒钟内崩解）的剂型。这种独特的配方主要旨在提高依从性和便利性，特别是对于吞嚥传统口服固体製剂（如锭剂和胶囊）有困难的患者。 ODT 通常用于给药，特别是那些需要快速起效的药物，例如止痛药、抗组织胺药物和用于治疗各种疾病的药物。

市场动态：

全球老年人口的增加预计将推动全球口溶锭市场的成长。由于可用性和便利性，老年人更喜欢自我给药给药。对老年人医疗保健设施的日益关注也推动了市场的成长。

然而，价格压力正在增加，预计将在不久的将来阻碍全球口溶锭市场的成长。

本研究的主要特点

• 本报告对全球口溶锭市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030）的市场规模和復合年增长率。
• 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
• 它根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球口溶锭市场的主要企业。
• 该报告的见解使行销人员和经营团队负责人就未来的产品发布、类型升级、市场扩张和行销策略做出资讯的决策。
• 全球口溶锭市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于分析全球口溶锭市场的各种策略矩阵，将促进相关人员的决策。

目录

第1章研究目的与前提

• 研究目标
• 假设
• 简称

第2章市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第3章市场动态、法规及趋势分析

• 促进因素
  • 市场动态
• 慢性病盛行率增加
• 药物传输技术的进步
• 提高患者的依从性和便利性
• 越来越注重以病人为中心的护理
  • 抑制因素
• 开发和製造成本高
• 有限的药物相容性和配方选择
  • 机会
• 对个人化医疗的需求不断增加
• 更多采用数位健康解决方案
• 开发创新的掩味技术
• 专注于速溶製剂
• 影响分析
• 主要亮点
• 监管场景
• 产品发布/核准
• PEST分析
• 波特的分析
• 併购场景

第4章全球口溶锭市场－冠状病毒（COVID-19）大流行的影响

• 新型冠状病毒感染疾病（COVID-19）的流行病学
• 供需面分析
• 经济影响

第5章全球口溶锭市场，依药物类别，2018-2030

• 止痛药
• 止吐药
• 抗精神病药
• 发炎药
• 镇静剂/安眠药
• 抗高血压
• 其他的

第6章全球口溶锭市场（依疾病适应症），2018-2030

• 疼痛管理
• 过敏及呼吸道疾病
• 神经系统疾病
• 胃肠道疾病
• 心血管疾病
• 其他的

第7章全球口溶锭市场，依年龄组别，2018-2030

• 儿童患者
• 成年患者
• 老年病人

第8章全球口溶锭市场，依配销通路，2018-2030

• 医院药房
• 零售药房
• 线上药房

第9章2018-2030年全球口溶锭市场（按地区）

• 北美洲
• 美国
• 加拿大
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 中国
• 印度
• 日本
• ASEAN
• 澳洲
• 韩国
• 其他亚太地区
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲
• 中东和非洲
• GCC
• 以色列
• 北非
• 中部非洲
• 其他中东和非洲

第10章竞争形势

• AstraZeneca PLC
• GlaxoSmithKline PLC
• Novartis International AG
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Cipla Limited
• Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals, Inc.
• Torrent Pharmaceuticals Ltd.
• F.Hoffmann-La Roche Ltd.
• Eisai Co., Ltd.
• Takeda Pharmaceutical Company Limited

第11章章节

• 调查方法
• 关于出版商

Global orodispersible tablets market is estimated to be valued US$ 9.29 billion in 2023. Over the forecast period, global orodispersible tablets market is expected to exhibit a compound annual growth rate (CAGR) of approximately 10.7%. By 2030, the market size is anticipated to reach USD 18.92 billion.

Figure 1. Global Orodispersible Tablets Market Share (%), By Region, 2023

Orodispersible tablets (ODTs) are solid unit dosage forms that disintegrate or dissolve rapidly in the mouth without chewing and without the need for water. The demand for this dosage form has been increasing, especially in pediatric and geriatric patient populations who find swallowing conventional tablets difficult or uncomfortable. ODTs are formulated from various excipients including binders and disintegrants. The most common binders are methacrylic acid copolymers that have high internal strength to support the formulation of high dose drugs. These also have the property of water resistance, and are less sensitive to moisture than standard tablet formulations. The most popular disintegrants are mannitol and aspartame. Orodispersible tablets (ODTs) are a specialized dosage form designed to disintegrate rapidly in the oral cavity, often within a matter of seconds, without the need for additional water or chewing. This unique pharmaceutical formulation is primarily intended to improve patient compliance and convenience, particularly for those who have difficulty swallowing traditional solid oral dosage forms like tablets or capsules. ODTs are commonly used to administer medications, including pain relievers, antihistamines, and treatments for various medical conditions, especially when quick onset of action is essential.

Market Dynamics:

Increasing geriatric population across the globe is anticipated to drive growth of the global orodispersible tablets market. Elderly people prefer self-administration of medications for easy accessibility and convenience. Rising focus on healthcare facilities for the elderly also boosts the market growth.

However, increased pricing pressure is projected to hinder growth of the global orodispersible tablets market in the near future.

Key features of the study:

• This report provides in-depth analysis of the global orodispersible tablets market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global orodispersible tablets market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca PLC, GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., Cipla Limited, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global orodispersible tablets market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global orodispersible tablets market

Detailed Segmentation:

• By Drug Class:
  • Analgesics
  • Antiemetics
  • Antipsychotics
  • Anti-inflammatory Drugs
  • Sedatives/Hypnotics
  • Antihypertensives
  • Others
• By Disease Indication:
  • Pain Management
  • Allergy and Respiratory Disorders
  • Neurological Disorders
  • Gastrointestinal Disorders
  • Cardiovascular Disorders
  • Others
• By Age Group:
  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East &Africa
• Company Profiles:
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Novartis International AG
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Torrent Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Eisai Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Orodispersible Tablets, By Drug Class
  • Market Orodispersible Tablets, By Disease Indication
  • Market Orodispersible Tablets, By Age Group
  • Market Orodispersible Tablets, By Distribution Channel
  • Market Orodispersible Tablets, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Drivers
  • Market Dynamics
• Increasing Prevalence of Chronic Diseases
• Technological Advancements in Drug Delivery
• Enhanced Patient Compliance and Convenience
• Growing Focus on Patient-Centered Care
  • Restraints
• High Development and Manufacturing Costs
• Limited Drug Compatibility and Formulation Options
  • Opportunities
• Increasing Demand for Personalized Medicine
• Rising Adoption of Digital Health Solutions
• Development of Innovative Taste-Masking Techniques
• Focus on Fast-Dissolving Formulations
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Orodispersible Tablets Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Orodispersible Tablets Market, By Drug Class, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019 - 2030
  • Segment Trends
• Analgesics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Antiemetics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Antipsychotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Anti-inflammatory Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Sedatives/Hypnotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Antihypertensives
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Orodispersible Tablets Market, By Disease Indication, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Allergy and Respiratory Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Gastrointestinal Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Cardiovascular Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Orodispersible Tablets Market, By Age Group, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2023- 2030
  • Segment Trends
• Pediatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Adult Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Geriatric Patients
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Orodispersible Tablets Market, By Distribution Channel, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2019- 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

9. Global Orodispersible Tablets Market, By Region, 2018-2030, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2030
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
• GCC
• Israel
• North Africa
• Central Africa
• Rest of Middle East & Africa

10. Competitive Landscape

• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline PLC
• Novartis International AG
• Johnson & Johnson Services, Inc.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Cipla Limited
• Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Lupin Pharmaceuticals, Inc.
• Torrent Pharmaceuticals Ltd.
• F.Hoffmann-La Roche Ltd.
• Eisai Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Analyst Views

11. Section

• Research Methodology
• About us